Core Scientific heads into this week with a sharp contradiction at its core — the Street is aggressively lifting targets after a strong earnings beat, yet short sellers are actually adding rather than running.
The analyst signal is the standout this week. Following the Q1 print, target prices moved sharply higher across the board. Jefferies raised its target to $37 — a 54% premium to Tuesday's close of $22.92 — while maintaining Buy. BTIG lifted to $33 and Macquarie moved to $35, both keeping positive ratings. Needham nudged to $29. Every move in the past two weeks has been a raise. The mean consensus target now sits at roughly $29.77, implying roughly 30% upside from current levels. The unanimity is notable: no downgrades, no price-target cuts, just a chorus of analysts recalibrating upward after the quarterly numbers came in stronger than expected. EPS surprise ranks in the 100th percentile, and 90-day EPS momentum is near the top of the universe. On valuation, EV/EBITDA of 21.7x has compressed about 2x over the past 30 days as earnings estimates moved higher — the multiple is tightening against an improving fundamental picture.
The short interest story cuts the other way. Positioning is heavily bearish and actually got more so in May. Short interest jumped to around 25.5% of the free float — up from roughly 23% at the end of April — driven by a noticeable step-up in borrowed shares around May 9th, when short positions expanded by more than six million shares in a single week. That's not the behavior of short sellers in retreat. Days to cover stand at 4.4. The borrow market remains loose, however, with availability at 337% — meaning there are more than three shares available to borrow for every one currently shorted. Cost to borrow is just 0.49%, barely above zero. That combination tells its own story: it's cheap and easy to stay short, and bears are taking advantage of that. The ORTEX short score of 63 puts CORZ in heavily shorted territory relative to peers, but nowhere near a squeeze setup given how ample the lending pool remains.
Options positioning is mildly defensive but not alarmed. The put/call ratio edged up to 0.52, fractionally above its 20-day average of 0.51 — a z-score of roughly 1.2, nowhere near extreme. The 52-week range runs from 0.24 to 0.63, so current readings sit comfortably in the middle. The options market is not flashing urgency in either direction.
Insider selling adds texture to the bear case. The Chief Legal Officer, Todd DuChene, has sold roughly 10,000 shares every week for the past six weeks in a pattern that looks mechanical — likely a pre-scheduled 10b5-1 plan. More notable is CEO Adam Sullivan, who sold 87,355 shares on April 15 at $19.08, netting around $1.67 million. Net insider flows over the past 90 days show net selling of around $7.8 million against roughly 480,000 net shares sold. Senior insiders are distributing into the rally that has taken the stock from the mid-teens to the low-to-mid $20s. That's consistent with a management team that believes the current price is fair or full, even if the Street thinks there's more to come.
On the institutional side, the top holders tell a mixed story. Vanguard and BlackRock hold passive positions and have barely moved. UBS Asset Management added more than five million shares in Q1, while Clearline Capital added 3.4 million. Pentwater trimmed by 763,000, and Two Seas cut its position by 2.9 million shares. Active money is rotating, not piling in uniformly. Peer context is also worth noting: while CORZ managed a slim 0.6% gain over the past week, close digital-infrastructure peers were broadly weaker — HUT dropped 13%, IREN fell 16%, WULF slid 6.4%, and RIOT lost 7.6%. That relative resilience reflects the company's differentiated HPC colocation positioning, but it also means CORZ has absorbed less of the sector selldown — leaving more potential downside if the broader crypto-infrastructure complex continues to weaken.
The key question heading into August earnings is whether the HPC colocation pipeline — the bull case's central pillar — translates into signed contracts and concrete revenue ramp, or whether customer concentration risk and buildout financing pressures begin to show through in the numbers.
See the live data behind this article on ORTEX.
Open CORZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
